CFO4Life Group LLC Has $716,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

CFO4Life Group LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 920 shares of the company’s stock after selling 50 shares during the period. CFO4Life Group LLC’s holdings in Eli Lilly and Company were worth $716,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $344,000. Graham Capital Management L.P. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $2,593,000. Trust Co. of Vermont grew its stake in Eli Lilly and Company by 0.8% during the third quarter. Trust Co. of Vermont now owns 7,404 shares of the company’s stock worth $3,977,000 after purchasing an additional 57 shares during the period. USA Financial Formulas grew its stake in Eli Lilly and Company by 8,433.3% during the third quarter. USA Financial Formulas now owns 256 shares of the company’s stock worth $138,000 after purchasing an additional 253 shares during the period. Finally, Scarborough Advisors LLC acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $233,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Barclays raised their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday. Berenberg Bank raised their target price on Eli Lilly and Company from $850.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup increased their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Argus increased their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $843.00.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders sold 1,214,704 shares of company stock valued at $1,066,841,316 over the last ninety days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $13.73 on Friday, reaching $947.87. 1,499,303 shares of the company’s stock traded hands, compared to its average volume of 2,925,251. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market cap of $900.87 billion, a PE ratio of 139.25, a PEG ratio of 2.05 and a beta of 0.41. The stock’s 50 day simple moving average is $845.17 and its two-hundred day simple moving average is $760.02. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $950.79.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same period last year, the business posted $1.62 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.